VA-DXC-TECHNOLOGY
16.9.2019 15:02:12 CEST | Business Wire | Press release
Technology startups and scale-ups can pitch their innovation stories to insurance industry leaders and potentially showcase their solutions globally through the DXC Technology (NYSE: DXC) second annual DXC Invitational Americas . Competition finalists will have the opportunity to present before hundreds of insurance professionals at the DXC Insurance Conference 2019 , Nov. 11-14 in Miami.
The DXC Invitational Americas is one in a series of global competitions that aims to yield joint solutions to key insurance business challenges by tapping into top talent in the startup community. Late-stage startup and scale-up enterprises worldwide that have existing, market-ready products or solutions relevant to the insurance industry are encouraged to apply by midnight Eastern time on Oct. 6 to compete in two categories:
- Category 1: The Digital Insurance Ecosystem: A product or solution that can be integrated into the DXC Assure Digital Platform.
- Category 2: Enriching the Insurance Experience: A standalone product or solution with the capability to on-sell as a DXC service.
Competition finalists and winners will be selected by a panel of DXC insurance industry clients, other industry experts, and DXC leadership. DXC will continue to explore collaborative opportunities with winners, including partnership possibilities and engagement with its global client base, which represents 85 percent of the Global Fortune 500 insurance companies.
Winners and finalists will be invited to attend the DXC Insurance Conference, where they will present their innovations to several hundred DXC clients, partners and employees. The winners, including a “People’s Choice” winner, will be formally announced at the conference.
“As a world leader in insurance technology and services, DXC proactively pursues new ways of collaborating with insurtech companies to accelerate the innovation cycle and jointly leverage capabilities that will give DXC insurance clients ready access to the newest, most advanced technologies,” said Phil Ratcliff, vice president and general manager of Global Insurance, DXC. “The winning solutions from the 2019 DXC Invitational competition will become part of the DXC Assure Digital Platform, which makes innovative technology easily accessible to our insurance clients.”
In addition to the inaugural global DXC Invitational in 2018, the company has conducted regional invitationals in Australia, North and Central Europe, and India.
“We have enjoyed great success with previous Invitational winners, Mapcite [Australia 2018] and Surfly [Americas 2018],” said Faisal Siddiqi, chief technologist for innovation and ecosystems, DXC. “Our collaboration with insurtech companies further expands the value of our digital platform to bring even more creative solutions and innovations to insurers through such technologies as blockchain, artificial intelligence and internet of things for more compelling customer experiences.”
To participate in the DXC Invitational Americas 2019, apply here .
About DXC Technology
DXC Technology, the world’s leading independent, end-to-end IT services company, manages and modernizes mission-critical systems, integrating them with new digital solutions to produce better business outcomes. The company’s global reach and talent, innovation platforms, technology independence and extensive partner network enable more than 6,000 private- and public-sector clients in 70 countries to thrive on change. For more information, visit www.dxc.technology .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190916005128/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom